172 related articles for article (PubMed ID: 31963723)
21. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
Ding L; Wang ZZ; Sun XD; Yang J; Ma CY; Li W; Liu HM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3521-3528. PubMed ID: 28610981
[TBL] [Abstract][Full Text] [Related]
22. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
[TBL] [Abstract][Full Text] [Related]
23. Integrated molecular docking, 3D QSAR and molecular dynamics simulation studies on indole derivatives for designing new Pim-1 inhibitors.
Peddi SR; Peddi SR; Sivan S; Veerati R; Manga V
J Recept Signal Transduct Res; 2020 Feb; 40(1):1-14. PubMed ID: 31931654
[TBL] [Abstract][Full Text] [Related]
24. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
Arsova A; Møller TC; Vedel L; Hansen JL; Foster SR; Gregory KJ; Bräuner-Osborne H
Mol Pharmacol; 2020 Jul; 98(1):49-60. PubMed ID: 32358164
[TBL] [Abstract][Full Text] [Related]
25. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.
Chen Y; Nong Y; Goudet C; Hemstapat K; de Paulis T; Pin JP; Conn PJ
Mol Pharmacol; 2007 May; 71(5):1389-98. PubMed ID: 17303702
[TBL] [Abstract][Full Text] [Related]
26. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
[TBL] [Abstract][Full Text] [Related]
27. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and mechanism of casein kinase II inhibitors.
Ul-Haq Z; Ashraf S; Bkhaitan MM
J Biomol Struct Dyn; 2019 Mar; 37(5):1120-1135. PubMed ID: 29527958
[TBL] [Abstract][Full Text] [Related]
28. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR CoMFA study of benzoxazepine derivatives as mGluR5 positive allosteric modulators.
Lowe EW; Ferrebee A; Rodriguez AL; Conn PJ; Meiler J
Bioorg Med Chem Lett; 2010 Oct; 20(19):5922-4. PubMed ID: 20732812
[TBL] [Abstract][Full Text] [Related]
31. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5).
Williams DL; Lindsley CW
Curr Top Med Chem; 2005; 5(9):825-46. PubMed ID: 16178729
[TBL] [Abstract][Full Text] [Related]
32. In silico study on β-aminoketone derivatives as thyroid hormone receptor inhibitors: a combined 3D-QSAR and molecular docking study.
Wang FF; Yang W; Shi YH; Le GW
J Biomol Struct Dyn; 2016 Dec; 34(12):2619-2631. PubMed ID: 26618241
[TBL] [Abstract][Full Text] [Related]
33. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
J Biomol Struct Dyn; 2018 May; 36(6):1463-1478. PubMed ID: 28482755
[TBL] [Abstract][Full Text] [Related]
34. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
[TBL] [Abstract][Full Text] [Related]
35. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
36. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
[TBL] [Abstract][Full Text] [Related]
37. Allosteric Modulation Mechanism of the mGluR
Cong X; Chéron JB; Golebiowski J; Antonczak S; Fiorucci S
J Chem Inf Model; 2019 Jun; 59(6):2871-2878. PubMed ID: 31025859
[TBL] [Abstract][Full Text] [Related]
38. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
39. Structural features of falcipain-3 inhibitors: an in silico study.
Wang J; Li F; Li Y; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2296-310. PubMed ID: 23765034
[TBL] [Abstract][Full Text] [Related]
40. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
